CAMKIIγ is a targetable driver of multiple myeloma through CaMKIIγ/ Stat3 axis

Aging (Albany NY). 2020 Jul 13;12(13):13668-13683. doi: 10.18632/aging.103490. Epub 2020 Jul 13.

Abstract

Aberrant activation of CAMKIIγ has been linked to leukemia and T-cell lymphoma, but not multiple myeloma (MM). The purpose of this study was to explore the role of CaMKIIγ in the pathogenesis and therapy of MM. In this study, we found that CaMKIIγ was aberrantly activated in human MM and its expression level was positively correlated with malignant progression and poor prognosis. Ectopic expression of CaMKIIγ promoted cell growth, colony formation, cell cycle progress and inhibited apoptosis of MM cell lines, whereas, knockdown of CAMKIIγ expression suppressed MM cell growth in vitro and in vivo. Mechanically, we observed that CaMKIIγ overexpression upregulated p-ERK and p-Stat3 levels and suppression of CaMKIIγ had opposite effects. CaMKIIγ is frequently dysregulated in MM and plays a critical role in maintaining MM cell growth through upregulating STAT3 signaling pathway. Furthermore, our preclinical studies suggest that CaMKIIγ is a potential therapeutic target in MM, and could be intervened pharmacologically by small-molecule berbamine analogues.

Keywords: CaMKIIγ; Stat3; multiple myeloma; poor prognosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Animals
  • Apoptosis / drug effects
  • Benzylisoquinolines / pharmacology*
  • Benzylisoquinolines / therapeutic use
  • Calcium-Calmodulin-Dependent Protein Kinase Type 2 / antagonists & inhibitors
  • Calcium-Calmodulin-Dependent Protein Kinase Type 2 / genetics
  • Calcium-Calmodulin-Dependent Protein Kinase Type 2 / metabolism*
  • Cell Line, Tumor
  • Extracellular Signal-Regulated MAP Kinases / metabolism
  • Female
  • Gene Knockdown Techniques
  • Humans
  • Kaplan-Meier Estimate
  • MAP Kinase Signaling System / drug effects
  • Male
  • Mice
  • Middle Aged
  • Multiple Myeloma / diagnosis
  • Multiple Myeloma / drug therapy
  • Multiple Myeloma / mortality
  • Multiple Myeloma / pathology*
  • Neoplasm Staging
  • Phosphorylation / drug effects
  • STAT3 Transcription Factor / metabolism*
  • Up-Regulation / drug effects
  • Xenograft Model Antitumor Assays

Substances

  • Benzylisoquinolines
  • STAT3 Transcription Factor
  • STAT3 protein, human
  • CAMK2G protein, human
  • Calcium-Calmodulin-Dependent Protein Kinase Type 2
  • Extracellular Signal-Regulated MAP Kinases
  • berbamine